Targets › TPK1
1 program from 1 company in 1 trial: 1 Phase 3; Cardiovascular; next expected readout Jun 2027.
Catalyzes the phosphorylation of thiamine to thiamine pyrophosphate (TPP) utilizing UTP and therefore links the biosynthesis of TPP to pyrimidines metabolism. By producing thiamine pyrophosphate, a cofactor of the mitochondrial pyruvate dehydrogenase indirectly regulates pyruvate oxidation and lipogenesis. (UniProt, Q9H3S4)
Open in Phaseline: the race on TPK1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hamilton Health Sciences Corporation | Thiamine Mononitrate Vitamin B1 (thiamine) cofactor involved in energy metabolism | TPK1 | Phase 3 | Heart Failure | Jun 2027 |
Heart Failure (1)
small molecule (1)
Hamilton Health Sciences Corporation (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.